{"filings":[{"id":225085,"accession_number":"0001493152-24-020133","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Panacea Life Sciences signs licensing deal with Sky Wellness for CBD product sales and development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue split: 40% net revenue to Panacea, 60% to Sky Wellness for existing CBD inventory.","Panacea to develop new products under Sky Wellness brands D Oh Gee (dog chews) and BoneUp (male enhancement).","Sky Wellness products to be sold in Panacea's six Pana Kava Java retail stores in Tampa, FL metro.","Sky Wellness retains full IP ownership; non-exclusive license granted to Panacea for manufacturing/marketing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225084,"accession_number":"0001493152-24-018058","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2024-05-07T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Panacea Life Sciences dismisses BF Borgers as auditor after SEC ban; no replacement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Dismissed BF Borgers CPA PC as independent auditor effective May 6, 2024, following SEC order barring BF Borgers from public practice.","No disagreements on accounting principles or reportable events other than previously disclosed material weaknesses in internal controls.","Audit reports for FY2022 and FY2023 were unqualified except for a going-concern explanatory paragraph.","Company has not yet engaged a new independent auditor but expects to do so quickly; change approved by Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244304,"accession_number":"0001493152-24-009173","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Panacea Life Sciences issues 666K shares to settle $100K note payment","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Converted $100,000 note payment to 666,000 shares of common stock on March 5, 2024.","Previous conversion in Feb 2023: 540,000 shares at $0.25/sh partially repaid the $385K note.","Original $385K Senior Convertible Note issued Mar 2022 in exchange for 350 Series A Preferred shares.","Company could not fund $100K cash payment due June 30, 2023; settled via stock conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244303,"accession_number":"0001493152-24-004908","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2024-02-05T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Panacea Life sells PUR Life assets to related party PLM Holdings for $180K note","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PLM Holdings (controlled by Panacea CEO and president) acquires all PUR Life assets and assumes related franchise liabilities.","Purchase price is a $180,000 promissory note, matching the initial deposit not refunded by PUR Life.","Prior PUR Life APA rescinded but company retained assets; now sold to related party on Jan. 29, 2024.","Transaction constitutes a related party transaction under Regulation S-K Item 404."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261725,"accession_number":"0001493152-23-044203","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K/A","filed_at":"2023-12-08T23:59:59+00:00","items":["9.01","2.01"],"status":"ready","headline":"Panacea Life Sciences Holdings files N7 Enterprises financials showing losses and going concern","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["N7 had $326k revenue and $82k net loss in 2022; 6mo2023 revenue $1.18M, net loss $147k.","Auditors express substantial doubt about N7's ability to continue as a going concern.","Acquisition consideration: 784 preferred shares convertible into 7.84M common shares of Panacea.","N7 started operations Nov 2022; negative cash flows and accumulated deficit noted.","Pro forma financials combine Panacea and N7 for six months ended June 30, 2023 and year ended Dec 31, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261727,"accession_number":"0001493152-23-036315","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2023-10-05T23:59:59+00:00","items":["1.01","2.01","3.02","5.03","7.01","9.01"],"status":"ready","headline":"Panacea Life Sciences acquires 8 Nitro Kava retail stores for 78,530 Series N-7 Preferred shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired 8 Nitro Kava retail stores and a distribution center in Tampa, FL from N7 Enterprises sellers.","Consideration: 78,530 shares of newly authorized Series N-7 Preferred (stated value $100/share, convertible 100:1 to common after 180 days).","N7 generated ~$2.6M revenue in FY2022 (unaudited); stores to be rebranded as PanaceaDistro with expansion and franchising plans.","Additional agreements: 6-month consulting with Gary Wilder at $20K/month, leakout restrictions on share sales, offset rights for acquisition expenses.","Series N-7 Preferred is senior to common but junior to existing preferred and debt, with no voting rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261726,"accession_number":"0001493152-23-034965","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2023-10-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Panacea Life Sciences acquires PUR Life Medical franchise for $1M cash plus up to $1.6M contingent","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $1M cash plus up to $1.6M payable over 4 years based on franchise fee and royalty collection.","Cash due in two tranches: $180,000 upon receipt of auditable financials and $820,000 on November 10, 2023.","Founder Dan Olsen (58.5% owner of PUR Life) retains 7% of new subsidiary; Panacea holds 93%.","Acquisition adds 60+ franchise locations, alternative medicine and pain management services to Panacea's vertical integration.","Panacea plans to finance the cash portion through debt and equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278928,"accession_number":"0001493152-23-024087","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2023-07-10T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Panacea Life Sciences to acquire eight Nitro Kava stores in Tampa for convertible preferred shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of 8 retail locations, distribution facilities, warehouse in Tampa area for 84,548 Series E convertible preferred shares.","Each preferred share convertible into 100 common shares after 180 days; sellers subject to 2-year lock-up with volume limits.","Acquired business generated $2.9M unaudited revenue in FY 2022; purchase price adjustable if closing monthly revenue <$175k.","Closing expected by Aug 31, 2023, subject to delivery of audited financials and other customary conditions.","Company also announced diversification into kratom, kava, functional mushrooms, and psychedelic research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297233,"accession_number":"0001493152-23-019955","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Panacea grants 1.11M shares to CEO, President, Board member, Controller in lieu of cash compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Leslie Buttorff (CEO) receives 760,000 shares for her 2023 annual salary.","Lawrence J. Wert (Board) receives 150,000 shares for 2022-2023 Board service.","Nick Cavarra (President) receives 150,000 shares for 2022 sales commissions.","Nathan Berman (Controller) receives 50,000 shares in lieu of salary increase.","50% of shares vest immediately; remaining vest on one-year anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317601,"accession_number":"0001493152-23-004634","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Panacea Life Sciences agrees to repay $385K convertible note via cash and equity conversion","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company to pay $135,000 funded under CEO line of credit on Feb 13, 2023; $100,000 by June 30, 2023.","Conversion of 540,000 common shares at fixed price of $0.25 per share to satisfy remaining balance.","Note Payoff Agreement dated Feb 9, 2023 amends prior Share Exchange Agreement from March 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317600,"accession_number":"0001493152-23-002132","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2023-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Panacea Life Sciences signs LOI to acquire N7 Enterprises for 22.2M shares","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Panacea will issue 22.2 million common shares to N7 Enterprises stockholders.","N7 Enterprises had $4.1M revenue in FY2022 and estimated net income exceeding $1M.","Expected close on or around February 28, 2023, subject to due diligence and definitive agreement.","N7 operates Florida kava/kratom lounges (Lizard Juice, N7 Nitro Kava) and a distribution subsidiary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335832,"accession_number":"0001493152-22-036518","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2022-12-27T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Panacea repays $1.11M convertible note; CEO credit line raised to $5M","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid $1,110,306.85 on Dec 21, 2022 to retire a 10% OID senior convertible note issued Nov 2021.","Original note had $1.1M principal, 10% discount, and warrants for 785,715 shares at $1.40/share.","Funding came from CEO line of credit, which was amended to increase borrowing capacity to $5M.","Note maturity was Nov 16, 2022; repayment satisfied all obligations under the Purchase Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353256,"accession_number":"0001493152-22-020148","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2022-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Janice Nerger resigns from Panacea Life Sciences board effective July 21, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Janice Nerger resigned from the board effective July 21, 2022, to accept interim provost role at Colorado State University.","Resignation is effective immediately; no replacement or further details provided.","Board size and remaining directors not disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370965,"accession_number":"0001493152-22-016384","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Panacea Life Sciences CEO presents to investors; presentation content not summarized (confidence low)","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation made on June 8, 2022 by CEO Leslie Buttorff to investment community.","Exhibit 99.1 contains the presentation, but its content is not provided in this filing summary.","No material financial or operational details available from filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370964,"accession_number":"0001493152-22-011933","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2022-05-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"CEO Leslie Buttorff presented to investors on May 3, 2022; no specifics disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["CEO Leslie Buttorff made a presentation to certain members of the investment community on May 3, 2022.","Presentation was furnished as Exhibit 99.1 but its substantive content is not included in this filing.","No financial results, projections, or material events were disclosed in the 8-K or attached exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389978,"accession_number":"0001493152-22-006060","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2022-03-04T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Panacea exchanges 350 Series A shares for $385K convertible note & warrants","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $385K 10% OID senior convertible note due March 2023, convertible at $1.40/sh.","Issued five-year warrants to purchase 275,000 shares at $1.40/sh, exercisable from May 18, 2022.","Note and warrants issued in exchange for 350 shares of 0% Series A Convertible Preferred Stock under MFN rights.","Note has 18% default interest, 125% redemption premium, and conversion adjustments including Qualified Offering.","Registration rights agreement subordinated to prior November 2021 private placement investor's rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407954,"accession_number":"0001493152-21-032695","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-12-29T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Panacea Life Sciences dismisses auditor RBSM, appoints BF Borgers as new independent accountant","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed RBSM LLP as independent auditor effective December 28, 2021.","RBSM's reports for FY 2020 and 2019 included going concern explanatory paragraphs.","No disagreements or reportable events between company and RBSM during relevant periods.","Appointed BF Borgers CPA PC as new independent registered public accounting firm on same date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407953,"accession_number":"0001493152-21-031991","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-12-20T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Panacea Life Sciences restates Q3 2021 financials; board cites errors in revenue, COGS, leases, warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concluded Q3 2021 unaudited financials filed Nov 22 should no longer be relied upon due to errors in revenue, cost of goods sold, lease liability, options and warrants.","Restated financials filed in amended 10-Q/A on Dec 17, 2021, affecting balance sheet, income statement, equity, and cash flow statements.","Original 10-Q was not reviewed by independent accountant RBSM prior to filing; amended report was reviewed and may be relied upon.","Board and CEO discussed the non-reliance determination with representatives of RBSM."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407949,"accession_number":"0001493152-21-031864","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K/A","filed_at":"2021-12-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Panacea Life Sciences 2020 revenue $9.0M, net loss $5.2M; auditor raises going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Revenue $9.0M in 2020 vs $2.2M in 2019; net loss $5.2M vs $2.8M.","Cash dropped to $84K from $8.5M year-end 2019; total assets $31.4M, liabilities $24.7M.","Auditor raises going concern due to recurring losses; company needs additional capital.","Related party note payable $15.1M at Dec 2020; $1M additional financing received Nov 2021.","Marketable securities (XXII shares) valued at $2.85M; unrealized gain $1.43M in 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407952,"accession_number":"0001493152-21-030226","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-12-01T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Panacea Life Sciences closes $1M private placement on Nov 30, 2021","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed private placement previously announced on Nov 24, 2021; received $1,000,000 wire.","Transaction closed on November 30, 2021 as a material definitive agreement.","No additional terms regarding security type or conversion were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407951,"accession_number":"0001493152-21-029840","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-11-24T23:59:59+00:00","items":["1.01","2.03","3.02","9.01"],"status":"ready","headline":"Panacea Life Sciences secures $1M via convertible note and warrant sale to Lincoln Park Capital","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Sold $1.1M senior convertible note (net $1M) and warrants for 785,715 shares at $1.40 to Lincoln Park Capital Fund.","Note due Nov 18, 2022; 12% interest if SEC filings missed, 18% on default; conversion at $1.40.","Warrants exercisable from May 18, 2022 for 5 years at $1.40; 4.99% beneficial ownership cap.","Investor may buy an additional $1.1M note and warrants on same terms within 91 business days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407950,"accession_number":"0001493152-21-026723","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-10-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Exactus renamed Panacea Life Sciences; 1-for-28 reverse split; Series C-2 preferred issued to cancel 205M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changed name to Panacea Life Sciences Holdings, Inc., effective Oct 25, 2021.","Effected 1-for-28 reverse stock split of common stock.","Designated 100 shares of Series C-2 Convertible Preferred stock, each convertible into 2,050,000 common shares.","Issued all 100 Series C-2 shares to Quintel-MC Inc., owned by CEO Leslie Buttorff, in exchange for canceling 205,000,000 common shares.","CEO Leslie Buttorff is sole owner, officer, and director of Quintel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407948,"accession_number":"0001493152-21-025975","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-10-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Exactus adds Dr. Janice Nerger to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Janice Nerger officially became a director on October 17, 2021.","Appointment followed compliance with Rule 14f-1 under the Exchange Act.","No other changes to board or officer positions were disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426967,"accession_number":"0001493152-21-022923","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-09-16T23:59:59+00:00","items":["4.02"],"status":"ready","headline":"Exactus restates Q2 2021 financials; related-party revenue of $4.7M improperly recognized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board concluded Q2 2021 Form 10-Q cannot be relied upon due to material errors.","$4.7M inventory sale to related party (Chairman/CEO) was improperly recorded as revenue.","Transaction accounted for 92% of Q2 revenue and 83% of H1 2021 revenue.","Additional errors in cash flow classification, ROU assets, payables, and expenses under review.","Company will file an amended 10-Q as soon as practicable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426966,"accession_number":"0001654954-21-007742","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-07-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Exactus CEO Leslie Buttorff delivers investor presentation; no material details disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Leslie Buttorff presented to investment community on July 8, 2021.","Presentation slide deck furnished as Exhibit 99.1; content not included in this filing.","No financial results, guidance, or material events announced in the 8-K.","Filing does not contain specific updates on company operations or strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426965,"accession_number":"0001654954-21-007695","cik":1552189,"company_name":"PANACEA LIFE SCIENCES HOLDINGS, INC.","ticker":"PLSH","form_type":"8-K","filed_at":"2021-07-07T23:59:59+00:00","items":["1.01","3.02","5.02","5.03","7.01","9.01"],"status":"ready","headline":"Exactus acquires Panacea Life Sciences; Leslie Buttorff becomes CEO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exactus issues 473.6M common shares + preferred stock to acquire Panacea; Buttorff owns ~61% fully diluted.","Leslie Buttorff named CEO/CFO with $380K salary plus $2.2M in shares upon NASDAQ listing.","22nd Century Group (XXII) receives 11.6% stake in combined company after exchanging Panacea preferred.","Board reduced to two directors; future additions include XXII CEO Jim Mish and Dr. Janice Nerger.","Reverse stock split 1-for-28 approved; company to rename as Panacea Life Sciences Holdings, Inc."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":709145.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}